PKC inhibitors also alter Bcl-x alternative splicing in healthy but not in oncogenic cells [28], and a signaling pathway through PI3K is responsible for the changes in the Bcl-xL/Bcl-xS mRNA ratio in cancer tissues by affecting the expression of the splicing factor SAP155 [68]. The gene discussed is PRRT2; the disease is cancer.